Baseline characteristics and treatment responses in patients who had a mutational assessment close to or following progression or discontinuation of dasatinib therapy (n = 174) who did or did not develop a new BCR-ABL mutation
| . | With new mutation, n = 47 . | Without new mutation, n = 127 . |
|---|---|---|
| Male, no. (%) | 26 (55) | 57 (45) |
| Median age, y (range) | 60 (32-82) | 57 (20-85) |
| Median duration of CML, mo (range) | 72 (4-246) | 61 (4-163) |
| Highest imatinib dose, no. (%) | ||
| Less than 400 mg/d | 0 (0) | 1 (1) |
| 400 to 600 mg/d | 18 (38) | 85 (67) |
| More than 600 mg/d | 29 (62) | 41 (32) |
| Prior imatinib treatment, % | ||
| Less than 1 y | 5 (11) | 21 (17) |
| 1 to 3 y | 16 (34) | 51 (40) |
| More than 3 y | 26 (55) | 55 (43) |
| Other prior therapy, no. (%) | ||
| Interferon-α | 25 (53) | 79 (62) |
| Stem cell transplantation | 2 (4) | 7 (6) |
| Response achieved prior to imatinib failure, no. (%) | ||
| CHR | 34 (72) | 103 (81) |
| MCyR | 11 (23) | 32 (25) |
| CCyR | 8 (17) | 12 (9) |
| MMR | 4 (9) | 8 (6) |
| Baseline BCR-ABL mutation, no. (%) | ||
| Yes | 33 (70) | 47 (37) |
| No | 14 (30) | 80 (63) |
| Response achieved on dasatinib therapy, no. (%) | ||
| CHR | 40 (85) | 100 (79) |
| MCyR | 16 (34) | 26 (20) |
| CCyR | 11 (23) | 16 (13) |
| . | With new mutation, n = 47 . | Without new mutation, n = 127 . |
|---|---|---|
| Male, no. (%) | 26 (55) | 57 (45) |
| Median age, y (range) | 60 (32-82) | 57 (20-85) |
| Median duration of CML, mo (range) | 72 (4-246) | 61 (4-163) |
| Highest imatinib dose, no. (%) | ||
| Less than 400 mg/d | 0 (0) | 1 (1) |
| 400 to 600 mg/d | 18 (38) | 85 (67) |
| More than 600 mg/d | 29 (62) | 41 (32) |
| Prior imatinib treatment, % | ||
| Less than 1 y | 5 (11) | 21 (17) |
| 1 to 3 y | 16 (34) | 51 (40) |
| More than 3 y | 26 (55) | 55 (43) |
| Other prior therapy, no. (%) | ||
| Interferon-α | 25 (53) | 79 (62) |
| Stem cell transplantation | 2 (4) | 7 (6) |
| Response achieved prior to imatinib failure, no. (%) | ||
| CHR | 34 (72) | 103 (81) |
| MCyR | 11 (23) | 32 (25) |
| CCyR | 8 (17) | 12 (9) |
| MMR | 4 (9) | 8 (6) |
| Baseline BCR-ABL mutation, no. (%) | ||
| Yes | 33 (70) | 47 (37) |
| No | 14 (30) | 80 (63) |
| Response achieved on dasatinib therapy, no. (%) | ||
| CHR | 40 (85) | 100 (79) |
| MCyR | 16 (34) | 26 (20) |
| CCyR | 11 (23) | 16 (13) |
CML indicates chronic myeloid leukemia; CHR, complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; and MMR, major molecular response.